Healthy Living Clinic: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healthyliving.clinic in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.

1. 1

   “The following claim concerning compounded semaglutide products appears on your website:”

2. 2

   “• “It is also available under brand names like Wegovy, Ozempic, and Rybelsus.””

3. 3

   “Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

healthyliving.clinic resolved on 2026-08-09 and served a live 118KB WordPress site with a named medical director, a published helpline (1-800-599-3104), an intake quiz, and a semaglutide product page carrying a price, a strikethrough, a subscription frame and a working Add to cart ($299.00 marked down to $149.00/month). The controls run in the same pass separate a live site from a dead one: a deliberately non-existent domain failed DNS outright, and sema.bio — another recipient in this same 09/09/2025 sweep — returned 200 with a 114-byte registrar parking page. This is a check of whether the site is up and what it sells; it is not a check of anything the letter alleges.

The reason to slow down on this one is that it does not sound like advertising. "It is also available under brand names like Wegovy, Ozempic, and Rybelsus" has the cadence of a footnote — the kind of neutral aside a reader files as background rather than as a pitch, and therefore does not argue with. But read who "it" is. On a page selling a compounded semaglutide subscription, the sentence says the thing in the cart is the thing sold under those three names, and it says so without ever making a comparison anyone could test. A comparison invites a check: same active ingredient as what, in what amount, made by whom. "Also available under" forecloses the question — there is nothing to compare, because it has already asserted one product with several labels. What is actually true is narrower and matters at the price: the approved products carry approved labelling, a manufacturer standing behind a specific formulation, and lot-level accountability; a compounded preparation is made for an individual by a pharmacy, has none of that paperwork behind it, and its price is set by that pharmacy rather than by the brand. So the practical test for a shopper is to ask what the seller says the product IS, in its own words, when it is not naming a brand — and to notice whether the answer names the compounding pharmacy. Checked on 2026-08-09, this company does name a specific dispensing pharmacy with an address and phone number, which is more than most sellers in this collection disclose, and the cited sentence is no longer on the semaglutide product page; the explainer paragraph it sat in remains, minus the brand names. The letter concerns wording, makes no finding about how the product was made or what is in it, and FDA has not closed it out.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Healthy Living Clinic failed to respond.